Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.
about
Activation of Proinflammatory Responses in Cells of the Airway Mucosa by Particulate Matter: Oxidant- and Non-Oxidant-Mediated Triggering MechanismsWnt/β-catenin signaling modulates human airway sensitization induced by β2-adrenoceptor stimulation.Long-acting β2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells.Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolinProtective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation.Cyclic AMP: a selective modulator of NF-κB action.Airway epithelium-derived relaxing factor: myth, reality, or naivety?Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-κB-Mediated Inflammation.Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.TNF-α regulates natriuretic peptides and aquaporins in human bronchial epithelial cells BEAS-2B.Identification of nuclear factor-κB inhibitors and β2 adrenergic receptor agonists in Chinese medicinal preparation Fuzilizhong pills using UPLC with quadrupole time-of-flight MS.Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies.Corticosteroid and long-acting ß-agonist therapy reduces epithelial goblet cell metaplasia.Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD.A bronchoprotective role for in a murine model of lipopolysaccharide-induced airways inflammation
P2860
Q28390698-26DBD2E9-8C3E-49F0-B20B-987A9D9C842CQ34434700-539A37DB-3251-42B9-9E76-119B02C6E79DQ34637901-21F1DA69-2199-4033-AF1F-16FFDDF38E56Q34997388-3FA33ACF-3F2F-4354-AF1C-06C1EBB7FD12Q35617207-DF4D826F-557B-431C-A4B3-49BB23C3F971Q36255835-AFBA563D-16B9-4737-BEDA-51E23E4E39ABQ37899788-3EC34120-0FB1-4FE2-B82B-61F71D4A7ACDQ38074605-2E645FA0-5FD4-41F9-B543-4B511DB36EEBQ38449873-A755EFA9-B67A-4DD3-96A9-9AF56EC9AF65Q38959067-A5051AEC-820F-4C50-941A-B38E4E44EF6AQ39039821-CC0E4453-D4CC-4724-A9A9-D511D05E8590Q39081962-938FD439-27A0-4317-8988-161545CD3FFAQ41681579-8E1A93E9-9824-47F4-B479-8583E271B1CBQ47818177-E42FC34F-8F97-44B9-9943-43D2009F03B2Q55202240-8F342250-955B-42BB-9E12-93A1043DCFABQ57298374-D87A4246-B35A-45A3-B5D8-6FBE22364E38
P2860
Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Enhancement of inflammatory mediator release by beta
@nl
Enhancement of inflammatory me ...... rsed by glucocorticoid action.
@en
type
label
Enhancement of inflammatory mediator release by beta
@nl
Enhancement of inflammatory me ...... rsed by glucocorticoid action.
@en
prefLabel
Enhancement of inflammatory mediator release by beta
@nl
Enhancement of inflammatory me ...... rsed by glucocorticoid action.
@en
P2093
P2860
P1476
Enhancement of inflammatory me ...... rsed by glucocorticoid action.
@en
P2093
J Velayudhan
M A Giembycz
N S Holden
P2860
P304
P356
10.1111/J.1476-5381.2010.00708.X
P407
P577
2010-05-01T00:00:00Z